← Back to home

LIVER CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, GASTRIC ADENOCARCINOMA, CERVICAL CANCER, MSI-H COLORECTAL CANCER

Clinical trials for LIVER CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, GASTRIC ADENOCARCINOMA, CERVICAL CANCER, MSI-H COLORECTAL CANCER explained in plain language.

Never miss a new study

Get alerted when new LIVER CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, GASTRIC ADENOCARCINOMA, CERVICAL CANCER, MSI-H COLORECTAL CANCER trials appear

Sign up with your email to follow new studies for LIVER CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, GASTRIC ADENOCARCINOMA, CERVICAL CANCER, MSI-H COLORECTAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Terminated 1

New cancer drug combo tested in patients out of options

Disease control Terminated

This early-stage study tested the safety of a new two-drug immunotherapy combination (JS004 plus toripalimab) in patients with advanced solid tumors that had stopped responding to standard treatments. The trial enrolled 31 adults with cancers like liver, esophageal, and cervical …

Matched conditions: LIVER CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, GASTRIC ADENOCARCINOMA, CERVICAL CANCER, MSI-H COLORECTAL CANCER

Phase: PHASE1 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control

Last updated Apr 03, 2026 14:42 UTC

LIVER CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, GASTRIC ADENOCARCINOMA, CERVICAL CANCER, MSI-H COLORECTAL CANCER

Get alerted when new LIVER CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, GASTRIC ADENOCARCINOMA, CERVICAL CANCER, MSI-H COLORECTAL CANCER trials appear

New cancer drug combo tested in patients out of options